We provide you with 20 years of free, institutional-grade data for SMMT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SMMT. Explore the full financial landscape of SMMT stock.
Total insider purchase within 3 month on this page: $11,965,611
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| DUGGAN ROBERT W | Open Market Purchase | 338,394 | $17.68 | 2025-09-11 | |
| Zanganeh Mahkam | Open Market Purchase | 338,394 | $17.68 | 2025-09-11 | |
| Zanganeh Mahkam | Derivatives Exercise | 74,545 | 2025-06-02 | ||
| DUGGAN ROBERT W | Derivatives Exercise | 74,545 | 2025-06-02 | ||
| Anand Bhaskar | Grant, award...etc | 22,026 | $22.7 | 2024-09-13 | |
| Soni Manmeet Singh | Grant, award...etc | 44,052 | $22.7 | 2024-09-13 | |
| Huber Jeff | Grant, award...etc | 44,052 | $22.7 | 2024-09-13 | |
| Zanganeh Mahkam | Grant, award...etc | 44,052 | $22.7 | 2024-09-13 | |
| DUGGAN ROBERT W | Grant, award...etc | 3,325,991 | $22.7 | 2024-09-13 | |
| Anand Bhaskar | Initial | 2024-04-04 | |||
| Dhingra Ankur | Open Market Purchase | 100,000 | $3.75 | 2024-03-27 | |
| Zanganeh Mahkam | Open Market Purchase | 50,000 | $3.75 | 2024-03-27 | |
| Zanganeh Mahkam | Open Market Purchase | 34,321 | $3.72 | 2024-03-27 | |
| Zanganeh Mahkam | Open Market Purchase | 26,000 | $3.72 | 2024-03-27 | |
| Zanganeh Mahkam | Open Market Purchase | 5,000 | $2.07 | 2023-12-13 | |
| Dhingra Ankur | Open Market Purchase | 20,400 | $2.15 | 2023-12-13 | |
| Soni Manmeet Singh | Open Market Purchase | 2,976,190 | $1.68 | 2023-10-16 | |
| Dhingra Ankur | Open Market Purchase | 13,027 | $0.97 | 2023-03-08 | |
| DUGGAN ROBERT W | Open Market Purchase | 376,489,880 | $1.05 | 2023-03-08 | |
| Dhingra Ankur | Open Market Purchase | 221,020 | $1.05 | 2023-03-08 | |
| Zanganeh Mahkam | Open Market Purchase | 6,748,629 | $1.05 | 2023-03-08 | |
| Zanganeh Mahkam | Open Market Purchase | 804,672 | $1.05 | 2023-03-08 | |
| Zanganeh Mahkam | Open Market Purchase | 15,973,743 | $1.05 | 2023-03-08 | |
| Zanganeh Maky | Open Market Purchase | 1,030,925 | $0.97 | 2022-08-18 | |
| Zanganeh Maky | Open Market Purchase | 4,593,777 | $0.97 | 2022-08-18 | |
| Zanganeh Maky | Open Market Purchase | 184,430 | $0.97 | 2022-08-18 | |
| DUGGAN ROBERT W | Open Market Purchase | 94,849,203 | $0.97 | 2022-08-18 | |
| Dhingra Ankur | Open Market Purchase | 24,658 | $0.97 | 2022-08-17 | |
| Dhingra Ankur | Open Market Purchase | 11,557 | $0.97 | 2022-08-17 | |
| Dhingra Ankur | Initial | 2022-06-02 |
The information provided in this report about SMMT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Summit Therapeutics Inc(NASDAQ:SMMT) 
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product ca...
Website: http://www.summitplc.com
Founded: 2003
Full Time Employees: 70
Sector: Healthcare
Industry: Biotechnology